Back to News
Market Impact: 0.35
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
Source: globenewswire.com
Healthcare & BiotechProduct Launches
IMCIVREE is launching in Japan after MHLW approval for acquired hypothalamic obesity and inclusion on Japan’s National Health Insurance drug price list. It is the first therapy approved in Japan for patients with the condition.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- Apple’s new home devices are a bet on its upgraded Siri AI
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- Apple releases HomeView smart home hub with screen as showcase for Siri AI
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales